title: Safety and efficacy of ruxolitinib in a profoundly thrombocytopenic patient with myelofibrosis.
authors.affiliation: Department of Haematology, Tallaght Hospital, Tallaght, Dublin 24, Ireland.
authors.forename: C
authors.initials: C
authors.lastname: Armstrong
authors.forename: S W
authors.initials: SW
authors.lastname: Maung
authors.forename: P
authors.initials: P
authors.lastname: Neary
authors.forename: J
authors.initials: J
authors.lastname: McHugh
authors.forename: H
authors.initials: H
authors.lastname: Enright
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D008297:Male; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines; D012720:Severity of Illness Index; D013921:Thrombocytopenia / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib